ORIGINAL RESEARCH

Assessment of ocular manifestation frequency and quality of life in chronic myeloproliferative disorders

Yunusova EM, Mukhamadeev TR, Bakirov BA
About authors

Bashkir State Medical University, Ufa, Russia

Correspondence should be addressed: Elvira M. Yunusova
Lenina, 3, 450008, Ufa, Russia; ur.liam@61anilluniaz

About paper

Author contribution: Yunusova EM — data collection and analysis, writing of the manuscript; Mukhamadeev TR — consulting, scientific editing of the manuscript; Bakirov BA — study concept and design, consulting.

Compliance with ethical standards: the study was approved by the Ethical Review Board at the Bashkir State Medical University (Protocol № 10 of 25 November 2020); all patients provided written informed consent for participation in the study.

Received: 2022-05-02 Accepted: 2022-05-17 Published online: 2022-05-29
|

Chronic myeloproliferative disorders (CMPD) include hemoblastoses with abnormal proliferation of myeloid lineages and concomitant alterations in the peripheral blood indicators. The aim of this study was to assess the frequency and structure of ophthalmic complications as a quality of life factor in patients with CMPD. A group of patients with hemoblastoses of this type (n = 41) were surveyed using National Eye Institute Visual Function Questionnaire-25 along with a comprehensive examination by noninvasive ophthalmological techniques. The patients typically reported impaired visual acuity, visual discomfort and foreign body sensation in the eyes. Though many of the patients assessed their general health and vision as satisfactory, the vast majority (68.3%) expressed serious concerns about their visual abilities. The ophthalmological examination revealed various defects including refractive errors (61%), corkscrew dilation and tortuosity of conjunctival and retinal vessels (77.9%), recurrent subconjunctival hemorrhages (39%) and dilated optic nerve sheaths (36.6%). The survey data indicate that visual impairments significantly affect quality of life in patients with CMPD. Overall, the results underscore the importance of interdisciplinary approach in the management of patients with CMPD to enable early diagnosis and feasible correction of the ophthalmic component.

Keywords: quality of life, chronic myeloproliferative disorders, ocular manifestations

КОММЕНТАРИИ (0)